Dr. Joonhee Lim, MD
Rheumatology (Rheumatology Physician)
3645 S Rome St Ste 201
Gilbert, AZ 85297
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 896
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
AZ license 55529
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Arizona Arthritis and Rheumatology Associates P C (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 896
- Services billed
- 239,793
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 53,760 | 12 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 31,000 | 18 |
| Injection, romosozumab-aqqg, 1 mg | 28,770 | 33 |
| Injection, golimumab, 1 mg, for intravenous use | 22,494 | 34 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17,600 | 40 |
| Injection, denosumab, 1 mg | 14,460 | 146 |
| Injection, infliximab, excludes biosimilar, 10 mg | 5,500 | 26 |
| Injection, rituximab, 10 mg | 2,900 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,488 | 664 |
| Insertion of needle into vein for collection of blood sample | 1,025 | 530 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxychloroquine Sulfate Other prescribers in Gilbert, AZ | 487 |
| Methotrexate (methotrexate sodium) Other prescribers in Gilbert, AZ | 454 |
| Prednisone Other prescribers in Gilbert, AZ | 380 |
| Tramadol Hcl Other prescribers in Gilbert, AZ | 279 |
| Leflunomide Other prescribers in Gilbert, AZ | 188 |
| Gabapentin Other prescribers in Gilbert, AZ | 105 |
| Enbrel Sureclick (etanercept) Other prescribers in Gilbert, AZ | 104 |
| Folic Acid Other prescribers in Gilbert, AZ | 98 |
| Methylprednisolone Other prescribers in Gilbert, AZ | 81 |
| Duloxetine Hcl Other prescribers in Gilbert, AZ | 69 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 224 payments worth $4,163 in total to this clinician.
| AbbVie Inc. | $1,391 |
|---|---|
| Amgen Inc. | $878 |
| UCB, Inc. | $448 |
| Pfizer Inc. | $306 |
| Janssen Biotech, Inc. | $213 |
| Fresenius Kabi USA, LLC | $115 |
| Alexion Pharmaceuticals, Inc. | $110 |
| Novartis Pharmaceuticals Corporation | $98.96 |
| Food and Beverage | $4,163 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $3,288,453 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Eli Lilly and Company · Terminated · NCT05516758 - A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs
E.r. Squibb & Sons, L.l.c. - A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Us…
Takeda Pharmaceuticals U.S.A., Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A phase 4, prospective, open-label, single-arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with active psoriatic arthritis and overweight or obesity in clini…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.